Ipilimumab: all 592 studies that test it

Page 3 of 6. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.

• A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. DacarbazineCompletedNCT02545075Phase 3Results posted
• An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCompletedNCT02538666Phase 3Results posted
• Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results posted
• Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate CancerTerminatedNCT02506114Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryCompletedNCT02500797Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results posted
• An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02477826Phase 3Results posted
• Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaCompletedNCT02428192Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02408861Phase 1Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedNCT02388906Phase 3Results posted
• A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaTerminatedNCT02385669Phase 1/2Results posted
• An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfCompletedNCT02320058Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerActive, not recruitingNCT02314169Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy NaiveCompletedNCT02279862Phase 2Results posted
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinCompletedNCT02279732Phase 3Results posted
• Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCActive, not recruitingNCT02259621Phase 2Results posted
• RTA 408 Capsules in Patients With Melanoma - REVEALCompletedNCT02259231Phase 1/2Results posted
• A Phase I/II Study of Intratumoral Injection of SD-101CompletedNCT02254772Phase 1/2Results posted
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results posted
• Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02221739Phase 1/2Results posted
• High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryTerminatedNCT02203604Phase 2Results posted
• Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT02158520Phase 2Results posted
• GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain MetastasesCompletedNCT02115139Phase 2Results posted
• Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT02107755Phase 2Results posted
• Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic RadiosurgeryTerminatedNCT02097732Phase 2Results posted
• Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)CompletedNCT02089685Phase 1/2Results posted
• Immunotherapy Study for Patients With Stage IV MelanomaTerminatedNCT02054520Phase 2Results posted
• Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseCompletedNCT02046733Phase 2Results posted
• Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaCompletedNCT02032810Phase 1Results posted
• CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT02027935Phase 2Results posted
• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsCompletedNCT02017717Phase 3Results posted
• A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma PatientsCompletedNCT02009397Phase 1/2Results posted
• Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin DiftitoxTerminatedNCT02009384Phase 2Results posted
• Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsCompletedNCT01990859Phase 2Results posted
• Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV MelanomaTerminatedNCT01970527Phase 2Results posted
• A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT01928394Phase 1/2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic CancerCompletedNCT01896869Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)CompletedNCT01866319Phase 3Results posted
• HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4Results posted
• Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedNCT01844505Phase 3Results posted
• Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic MelanomaTerminatedNCT01838200Phase 1Results posted
• Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaCompletedNCT01827111Phase 2Results posted
• Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01820754Phase 2Results posted
• Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerCompletedNCT01804465Phase 2Results posted
• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)CompletedNCT01783938Phase 2Results posted
• A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCompletedNCT01714739Phase 1/2Results posted
• Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaTerminatedNCT01709162Phase 2Results posted
• Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsCompletedNCT01701674Not applicableResults posted
• Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaTerminatedNCT01696045Phase 2Results posted
• Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical CancerCompletedNCT01693783Phase 2Results posted
• Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaCompletedNCT01681212Phase 2Results posted
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results posted
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results posted
• PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCompletedNCT01621490Phase 1Results posted
• Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerCompletedNCT01611558Phase 2Results posted
• Doxycycline, Temozolomide and Ipilimumab in MelanomaTerminatedNCT01590082Phase 1/2Results posted
• An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line ChemotherapyCompletedNCT01585987Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaCompletedNCT01585194Phase 2Results posted
• First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial CarcinomaCompletedNCT01524991Phase 2Results posted
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg IpilimumabCompletedNCT01515189Phase 3Results posted
• Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedNCT01498978Phase 2Results posted
• RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMACompletedNCT01497808Phase 1/2Results posted
• Yervoy With Sylatron Unresectable Stage 3 or 4 MelanomaCompletedNCT01496807Phase 1Results posted
• Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT01473940Phase 1Results posted
• Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedNCT01472081Phase 1Results posted
• Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerTerminatedNCT01471197Phase 2Results posted
• Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)CompletedNCT01454102Phase 1Results posted
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneCompletedNCT01450761Phase 3Results posted
• Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation TherapyCompletedNCT01449279Phase 2Results posted
• Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TerminatedNCT01400451Phase 1Results posted
• Ipilimumab + Androgen Depravation Therapy in Prostate CancerTerminatedNCT01377389Phase 2Results posted
• Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityCompletedNCT01323517Phase 2Results posted
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinCompletedNCT01285609Phase 3Results posted
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT01274338Phase 3Results posted
• Neoadjuvant Ipilimumab in Prostate CancerCompletedNCT01194271Phase 2Results posted
• Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung CancerCompletedNCT01165216Phase 1Results posted
• Ipilimumab + Temozolomide in Metastatic MelanomaCompletedNCT01119508Phase 2Results posted
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate CancerCompletedNCT01057810Phase 3Results posted
• Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT01024231Phase 1Results posted
• Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced MelanomaCompletedNCT00920907Phase 1Results posted
• Study of Immunotherapy to Treat Advanced Prostate CancerCompletedNCT00861614Phase 3Results posted
• Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, DacarbazineCompletedNCT00796991Phase 1Results posted
• Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III MelanomaCompletedNCT00636168Phase 3Results posted
• Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)CompletedNCT00527735Phase 2Results posted
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaCompletedNCT00324155Phase 3Results posted
• Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00323882Phase 1/2Results posted
• Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate CancerCompletedNCT00170157Phase 2Results posted
• A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab StudiesCompletedNCT00162123Phase 2Results posted
• A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial SarcomaTerminatedNCT00140855Phase 2Results posted
• MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00112580Phase 2Results posted
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3Results posted
• MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
• Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue SarcomaSuspendedNCT06968988Phase 1
• A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06946797Phase 2
• Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruitingNCT06784648Phase 1/2
• Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic MelanomaActive, not recruitingNCT06566391Phase 2
• A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerWithdrawnNCT06410534Phase 2

← Ipilimumab overview